The Vanguard Group, Inc. recently announced the acquisition of new stake in Alaunos Therapeutics Inc (NASDAQ:TCRT). The institutional investor has increased its shareholding in the Healthcare company by 3.62% to 9.36 million shares with purchase of 0.33 million shares. This fresh investment now brings its stake to 3.89% valued currently at $0.62 million. In addition, Securities America Advisors, Inc. raised its holdings by 1300.0 to 0.61 million shares.
Currently, there are 240.41M common shares owned by the public and among those 229.69M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 1 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 68,014 shares.
The top 3 mutual fund holders in Alaunos Therapeutics Inc are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and JPMorgan Funds – Thematics – Gene. Vanguard Total Stock Market ETF owns 6.06 million shares of the company’s stock, all valued at over $0.4 million. JPMorgan Funds – Thematics – Gene sold -1.7 million shares to bring its total holdings to over 2.51 million shares at a value of $0.17 million. JPMorgan Funds – Thematics – Gene now owns shares totaling to 1.04% of the shares outstanding.
However, the script later moved the day high at 0.0640, up 26.15%. The company’s stock has a 5-day price change of 14.57% and -61.78% over the past three months. TCRT shares are trading -91.16% year to date (YTD), with the 12-month market performance down to -90.68% lower. It has a 12-month low price of $0.04 and touched a high of $0.86 over the same period. TCRT has an average intraday trading volume of 3.57 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.39%, -29.56%, and -82.99% respectively.
Institutional ownership of Alaunos Therapeutics Inc (NASDAQ: TCRT) shares accounts for 22.68% of the company’s 240.41M shares outstanding. Mutual fund holders own 20.19%, while other institutional holders and individual stakeholders account for 6.64% and 16.04% respectively.
It has a market capitalization of $13.81M and a beta (3y monthly) value of -0.23. The earnings-per-share (ttm) stands at -$0.15. Price movements for the stock have been influenced by the stock’s volatility, which stands at 23.85% over the week and 18.13% over the month.
Analysts forecast that Alaunos Therapeutics Inc (TCRT) will achieve an EPS of $Cross Timbers Royalty Trust for the current quarter, $18.46 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $TScan Therapeutics, Inc. while analysts give the company a high EPS estimate of $Trio-Tech International. Comparatively, EPS for the current quarter was $Recruiter.com Group, Inc. a year ago. Earnings per share for the fiscal year are expected to increase by 11.76%, and 73.33% over the next financial year.
Looking at the support for the TCRT, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on October 04, 2022, with the firm’s price target at $3.
